Delving into the Latest Updates on CC5-17 with Synapse

Author: Enos, Suzanne ; Pegan, Scott D ; Karakoc, Hanife Nur ; Bergeron, Éric ; Durie, Ian A ; Yilmaz, Gurdal ; Sorvillo, Teresa E ; Spiropoulou, Christina F ; Welch, Stephen R ; McGuire, Jack ; Harmon, Jessica R ; Kainulainen, Markus H ; Spengler, Jessica R ; Tehrani, Zahra R ; Gonzalez, David ; Garrison, Aura R ; Golden, Joseph W ; Hamidi, Sanaz ; Mousa, Jarrod J ; Karaaslan, Elif ; Albay, Cansu ; Sajadi, Mohammad M ; Koksal, Iftihar

AbstractCrimean-Congo Hemorrhagic Fever Virus (CCHFV) causes a life-threatening disease with up to a 40% mortality rate. With no approved medical countermeasures, CCHFV is considered a public health priority agent. The non-neutralizing mouse monoclonal antibody (mAb) 13G8 targets CCHFV glycoprotein GP38 and protects mice from lethal CCHFV challenge when administered prophylactically or therapeutically. Here, we reveal the structures of GP38 bound with a human chimeric 13G8 mAb and a newly isolated CC5-17 mAb from a human survivor. These mAbs bind overlapping epitopes with a shifted angle. The broad-spectrum potential of c13G8 and CC5-17 and the practicality of using them against Aigai virus, a closely related nairovirus were examined. Binding studies demonstrate that the presence of non-conserved amino acids in Aigai virus corresponding region prevent CCHFV mAbs from binding Aigai virus GP38. This information, coupled with in vivo efficacy, paves the way for future mAb therapeutics effective against a wide swath of CCHFV strains.

100 Deals associated with CC5-17

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhagic Fever, Crimean	Preclinical	US	University of Georgia	26 Nov 2022
Hemorrhagic Fever, Crimean	Preclinical	US	University of Maryland Baltimore	26 Nov 2022